Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) Director Sells 5,000 Shares of Stock

Blueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers sold 5,000 shares of Blueprint Medicines stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $102.28, for a total transaction of $511,400.00. Following the completion of the transaction, the director now directly owns 157,557 shares of the company’s stock, valued at $16,114,929.96. This trade represents a 3.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Blueprint Medicines Price Performance

NASDAQ BPMC opened at $110.05 on Friday. Blueprint Medicines Co. has a 12 month low of $72.24 and a 12 month high of $121.90. The firm has a market capitalization of $6.99 billion, a PE ratio of -52.16 and a beta of 0.61. The company’s 50 day simple moving average is $94.09 and its 200 day simple moving average is $95.42. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.08. The company had revenue of $128.20 million for the quarter, compared to analysts’ expectations of $127.56 million. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The firm’s revenue for the quarter was up 126.5% on a year-over-year basis. During the same period last year, the firm earned ($2.20) EPS. As a group, equities research analysts forecast that Blueprint Medicines Co. will post -3.68 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $135.00 target price on shares of Blueprint Medicines in a report on Monday, January 13th. Wedbush restated an “outperform” rating and set a $124.00 price objective (down previously from $135.00) on shares of Blueprint Medicines in a research report on Monday, January 13th. StockNews.com raised Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. JMP Securities reiterated a “market outperform” rating and issued a $125.00 target price on shares of Blueprint Medicines in a research note on Wednesday. Finally, Guggenheim restated a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Blueprint Medicines presently has an average rating of “Moderate Buy” and a consensus target price of $122.72.

Institutional Investors Weigh In On Blueprint Medicines

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Federated Hermes Inc. grew its stake in shares of Blueprint Medicines by 27.8% in the 2nd quarter. Federated Hermes Inc. now owns 62,354 shares of the biotechnology company’s stock worth $6,721,000 after purchasing an additional 13,579 shares during the last quarter. Massachusetts Financial Services Co. MA bought a new stake in Blueprint Medicines during the second quarter worth approximately $18,273,000. Citizens Financial Group Inc. RI acquired a new position in Blueprint Medicines in the second quarter worth approximately $423,000. Renaissance Technologies LLC increased its holdings in shares of Blueprint Medicines by 132.4% in the second quarter. Renaissance Technologies LLC now owns 110,400 shares of the biotechnology company’s stock valued at $11,899,000 after buying an additional 62,900 shares in the last quarter. Finally, Edgestream Partners L.P. acquired a new stake in shares of Blueprint Medicines during the 2nd quarter valued at $1,113,000.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.